BILL ANALYSIS

HR8471

BEARISH

PRIMATE Act

HR8471 (PRIMATE Act) has been assessed with a bearish outlook for investors. The primary sectors impacted are Healthcare and Agriculture. View the full bill text on Congress.gov.

bearish

Market Sentiment

4/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

The PRIMATE Act would ban import of nonhuman primates for research, increasing costs for CROs.

Charles River Laboratories ($CRL) and Inotiv ($NOTV) are directly exposed to this supply-side restriction.

Bill is in early stage; monitor committee action for progression and potential market impact.

How HR8471 Affects the Market

Current market impact is negligible as the bill is in early committee stage. However, $CRL and could face selling pressure if the bill gains legislative momentum. No real market data was provided, so no price references are included. Structural positioning: $CRL and are the most exposed, while alternative testing companies (e.g., organ-on-chip firms, mostly private) could benefit, but no public pure-play exists.

Bill Details

Metric	Value
Bill Number	HR8471
Market Sentiment	bearish
Event Date	April 23, 2026
Affected Sectors	Healthcare, Agriculture
Source	View on Congress.gov →

Summary

The PRIMATE Act (HR8471) would prohibit importation of nonhuman primates except for AZA-accredited zoos, effectively banning their use in biomedical research. This early-stage bill, if enacted, would be a structural headwind for contract research organizations (CROs) that rely on imported primates, particularly Charles River Laboratories ($CRL) and Inotiv ($NOTV).

Full AI Market Analysis

The PRIMATE Act (Preventing Risky Importation of Monkeys to Avoid Toxic Exposures Act) was introduced on April 23, 2026, by Rep. Steube (R-FL) and referred to the House Committee on Ways and Means. The bill amends the Tariff Act of 1930 to prohibit the importation of nonhuman primates into the United States, with a narrow exception for AZA-accredited facilities that certify the primates will not be used in experiments or testing. There is no funding authorization or appropriation in this bill; it is a regulatory prohibition enforced by U.S. Customs and Border Protection, with civil penalties up to $50,000 per violation. No related signals or procurement data were provided, so no convergence analysis is possible. The bill's primary market impact is on the biomedical research sector, specifically contract research organizations (CROs) that import nonhuman primates for drug development and toxicity testing. Charles River Laboratories ($CRL) and Inotiv are the two largest publicly traded CROs with significant primate importation and breeding operations. If enacted, the bill would create supply constraints, increase costs, and potentially delay research projects, reducing revenue for these companies. The bill is in the earliest legislative stage; it has 7 cosponsors from both parties, indicating some bipartisan support, but it must clear the Ways and Means Committee, pass the House, and then the Senate. Legislative progress is likely slow, and the bill's ultimate passage is uncertain.